Kognitive Verhaltenstherapie bei Personen mit erhöhtem Psychoserisiko

Zusammenfassung

Schizophrene Erkrankungen haben für die Betroffenen und ihre Angehörigen oft schwerwiegende Folgen und verursachen für die Gesellschaft immense Kosten, weshalb eine Prävention im Sinne einer Frühintervention bei Personen mit einem erhöhten Risiko, im weiteren Verlauf eine Psychose zu entwickeln, als dringend notwendig erscheint. Aus diesem Grund haben mehrere Forschergruppen Risikokriterien und mögliche Modelle für präventive Interventionen entwickelt. Der vorliegende Beitrag gibt eine Übersicht über die aktuellen Risikokriterien und den derzeitigen empirischen Stand der Interventionsforschung, um dann spezielle auf kognitiv verhaltenstherapeutische Strategien zur Psychoseprävention einzugehen.

Summary

Psychotic disorders often have devastating consequences for patients and their families and cause very high costs for society. Therefore, early intervention for people at high risk of developing psychosis is of high interest. As a result different research groups have developed at risk criteria and models for early intervention strategies. The present paper gives an overview of recent at risk criteria and preventive strategies, which have been empirically evaluated. It thereby focuses especially on cognitive behaviour therapy as a strategy for the prevention of psychosis.

Schlüsselwörter

Erhöhtes Psychoserisiko - Risikokriterien - Frühintervention - Kognitive Verhaltenstherapie

Keywords

People at high risk of developing psychosis - risk criteria - early intervention - cognitive-behavioral therapy

• Literatur

• 1 Angermeyer MC, Matschinger H. Public attitude towards psychiatric treatment. Acta Psychiatrica Scandinavica 1996; 94 (Suppl. 05) 326-336.
• 2 APA work group.. Practice guideline for the treatment of patients with panic disorder. American Journal of Psychiatry 1998; 155 (Suppl. 05) 1-34.
• 3 APA work group.. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000; 157 (Suppl. 04) 1-45.
• 4 Bechdolf A, Veith V, Berning J, Stamm E, Janssen B, Wagner M, Klosterkötter J. Cognitive-behavioural therapy in the pre-psychotic phase. An exploratory study. Psychiatry Research 2005; 136 2–3 251-255.
• 5 Bechdolf A, Wagner M, Veith V, Ruhrmann S, Brockhaus-Dumke A, Pukrop R, Berning J, Stamm E, Janssen B, Decker P, Bottlender R, Möller HJ, Gaebel W, Maier W, Klosterkötter J. A randomized controlled multicenter trial of cognitive behavior therapy in the early initial prodromal state: Effects on social adjustment post-treatment. Early Intervention in Psychiatry 2007; 1: 71-78.
• 6 Bell RQ. Multiple-risk cohorts and segmenting risks as solutions to the problem of false positives in risk for the major psychoses. Psychiatry 1992; 55: 370-381.
• 7 Bentall RP, Kinderman P, Kaney S. The self, attributional processes and abnormal beliefs: Towards a model of persecutory delusions. Behaviour Research and Therapy 1994; 32: 331-341.
• 8 Blackwood NJ, Howard RJ, Bentall RP, Murray RM. Cognitive neuropsychiatric model of persecutory delusions. American Journal of Psychiatry 2001; 158: 527-539.
• 9 Freeman D, Garety PA, Kuipers E. Persecutory delusions: developing the understanding of belief maintenance and emotional distress. Psychological Medicine 2001; 31: 1293-1306.
• 10 Garety PA, Hemsley DR. Delusions: Investigations into the Psychology of Delusional Reasoning. Oxford: Oxford University Press; 1994
• 11 Garety PA, Kuipers E, Fowler D, Freeman D, Bebbington PE. A cognitive model of the positive symptoms of psychosis. Psychological Medicine 2001; 31: 189-195.
• 12 Huber G, Gross G, Schüttler R. Schizophrenie. Verlaufs- und sozialpsychiatrische Langzeituntersuchung an den 1945–1959 in Bonn hospitalisierten schizophrenen Kranken. Berlin: Springer; 1979
• 13 Huber G. Das Konzept substratnaher Basissymptome und seine Bedeutung für Theorie und Therapie schizophrener Erkrankungen. Nervenarzt 1983; 54: 23-32.
• 14 Huber G. Psychiatrische Aspekte des Basisstörungskonzepts. In: Süllwold L, Huber G. (Hrsg.). Schizophrene Basisstörungen. Berlin, Heidelberg, New York: Springer; 1986: 39-143.
• 15 Jaspers K. Allgemeine Psychopathologie. Berlin: Springer; 1946
• 16 Kingdon D, Turkington D. Cognitive therapy of schizophrenia. New York: The Guilford Press; 2005
• 17 Kissling W, Hoffler J. et al. Direct and indirect costs of schizophrenia Fortschritte der. Neurologie und Psychiatrie 1999; 67 (Suppl. 01) 29-36.
• 18 Klosterkötter J. Basissymptome und Endphänomene der Schizophrenie. Springer. Berlin, Heidelberg, New York: Springer; 1988
• 19 Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry 2001; 58: 158-164.
• 20 Klosterkötter J, Ruhrmann S, Schultze-Lutter F. et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry 2005; 4 (Suppl. 03) 161-167.
• 21 Larsen TK, Bechdolf A, Birchwood M. The concept of schizophrenia and phase specific treatment. Psychological treatment in pre-psychosis and non-responders. J Am Acad Psychoanal Dyn Psychiatry 2003; 31 (Suppl. 01) 209-228.
• 22 Lauber C, Nordt C. et al. Lay recommendations on how to treat mental disorders. Social Psychiatry and Psychiatric Epidemiology 2001; 36 (Suppl. 11) 53-56.
• 23 McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW. et al. A randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry 2006; 163 (Suppl. 05) 790-799.
• 24 McGorry PD, Yung AR. et al. The NEURAPRO Study: A 15 centre RCT of treatment strategies for symptomatic patients at ultra-high risk for early progression to psychosis. Draft of proposal to be submitted for funding 2004
• 25 McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 2002; 59: 921-928.
• 26 Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, Woods SW. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry 2002; 159: 863-865.
• 27 Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP. A randomised controlled trial of early detection and cognitive therapy fort he prevention of psychosis in people at ultra-high risk. British Journal of Psychiatry 2004; 185: 291-297.
• 28 Murray CJL, Lopez AD. (eds.) The global burden of disease and injury series, vol. 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge MA: Harvard University Press; 1996
• 29 Nuechterlein KH, Dawson ME. A heuristic vulnerability/ stress model of schizophrenic episodes. Schizophrenia Bulletin 1984; 10: 300-312.
• 30 Ruhrmann S, Bechdolf A, Kühn KU, Wagner M, Schultze-Lutter F, Janssen B, Gaebel W, Möller HJ, Maier W, Klosterkötter J. for the LIPS study group.. Acute symptomatic treatment effects in persons putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry 2007; Suppl 51: 88-95.
• 31 Simon AE. et al. Defining subjects at risk for psychosis: A comparison of two approaches. Schizophrenia Research 2006; 81: 83-90.
• 32 Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD. Psychosis prediction: 12-month follow up of a highrisk (”prodromal”) group. Schizophrenia Research 2003; 60 (Suppl. 01) 21-23.
• 33 Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research 2004; 67: 131-142.
• 34 Yung AR, Phillips LJ, McGorry PD. et al. Prediction of psychosis. British Journal of Psychiatry 1998; 172 (Suppl. 33) 14-20.